Ractigen Therapeutics Advances RNAa Technology with Promising Clinical Trials for ALS and DMD

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering next-generation RNA therapeutics, has made significant strides in its pipeline of small activating RNA (saRNA) candidates, targeting previously untreatable diseases such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD). The company’s proprietary RNA activation (RNAa) technology, combined with its Smart Chemistry-Aided Delivery (SCAD™) platform, is reshaping the landscape of gene-targeted therapies.

The Science Behind RNAa and SCAD™ Technology

Ractigen’s RNAa technology leverages small activating RNA (saRNA) to selectively boost the expression of therapeutic genes in diseased cells. Unlike traditional RNA interference (RNAi) approaches that silence genes, RNAa works by activating gene expression, offering a novel mechanism to address genetic disorders. This technology is particularly promising for conditions where restoring gene function is critical, such as monogenic diseases.

Central to Ractigen’s advancements is its SCAD™ platform, which enhances the delivery of saRNA to the central nervous system (CNS) through a unique conjugation method. By attaching the saRNA duplex to an accessory oligonucleotide (ACO), SCAD™ enables widespread CNS distribution and prolonged target engagement following a single intrathecal injection. This innovation could reduce the frequency of dosing compared to existing therapies, improving patient compliance and outcomes.

Progress in Clinical Trials: RAG-17 for SOD1-ALS

Ractigen’s lead candidate, RAG-17, is in a Phase II clinical trial for SOD1-ALS, a rare and aggressive form of ALS caused by mutations in the superoxide dismutase 1 (SOD1) gene. Earlier this year, the company reported positive preliminary data from the single ascending dose (SAD) Phase I portion of the trial, presented at the 2026 American Academy of Neurology (AAN) Annual Meeting.

The Phase I trial demonstrated a 81% reduction in neurofilament light chain (NfL), a biomarker associated with neurodegeneration, following a single intrathecal dose of RAG-17. The therapeutic showed a favorable safety profile, with preliminary trends indicating clinical stabilization in patients, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). These results underscore the potential of RAG-17 to slow disease progression in SOD1-ALS patients.

“The data presented at AAN this year represents a major milestone for Ractigen and, more importantly, for patients living with SOD1-ALS,” said Dr. Long-Cheng Li, CEO of Ractigen Therapeutics. “RAG-17’s ability to achieve durable biomarker reductions with a single dose highlights the transformative potential of our SCAD™ platform.”

RAG-18: A New Hope for DMD Patients

In a separate initiative, Ractigen’s RAG-18 is being evaluated in an investigator-initiated trial (IIT) for DMD, a severe genetic disorder characterized by progressive muscle degeneration. RAG-18 employs saRNA to upregulate the expression of the *UTRN* gene, which encodes utrophin—a protein that can compensate for the absence of dystrophin, the defective protein in DMD.

The IIT, led by Professor Dai Yi at Peking Union Medical College Hospital (PUMCH), aims to assess RAG-18’s safety, pharmacokinetics, and potential to improve muscle function. “RAG-18 represents a revolutionary approach to treating DMD, offering a universal solution that could benefit all patients regardless of their genetic mutation,” said Professor Dai. “We anticipate positive clinical results that could open new treatment avenues for this devastating condition.”

Ractigen’s CEO, Dr. Li, emphasized the significance of RAG-18: “This treatment has the potential to address all genetic mutations related to DMD, demonstrating RNAa technology as a groundbreaking method in clinical practice.”

A Pipeline Targeting Previously Undruggable Diseases

Ractigen’s pipeline extends beyond ALS and DMD, addressing a range of “undruggable” diseases, including neurological and neuromuscular disorders, liver-related conditions, and oncology. The company’s